Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthrax

Infection and Immunity

Volumn 80, Issue 7, 2012, Pages 2414-2425

  Lovchik, Julie A ^a   Drysdale, Melissa ^a,d   Koehler, Theresa M ^b   Hutt, Julie A ^c   Lyons, C Rick ^a,e  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; BACTERIAL ANTIGEN; EDEMA TOXIN; LETHAL TOXIN; PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG; VINBLASTINE SULFATE;

AMES TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM MUTANT; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; GENE DELETION; HISTOPATHOLOGY; INHALATIONAL ANTHRAX; LETHAL GENE; LYMPH NODE; NONHUMAN; OPERON; PRIORITY JOURNAL; RABBIT; WILD TYPE;

ANIMALS; ANTHRAX; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL CAPSULES; BACTERIAL TOXINS; DISEASE MODELS, ANIMAL; FEMALE; GENE DELETION; HISTOCYTOCHEMISTRY; RABBITS; SURVIVAL ANALYSIS; VIRULENCE; VIRULENCE FACTORS;

EID: 84864360610     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.06340-11     Document Type: Article

References (81)

1. Abrami L, Lindsay M, Parton RG, Leppla SH, Van der Goot FG. 2004. Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway. J. Cell Biol. 166:645- 651.
2. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. 1993. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc. Natl. Acad. Sci. U. S. A. 90:2291-2294.
3. Batty S, Chow EM, Kassam A, Der SD, Mogridge J. 2006. Inhibition of mitogen-activated protein kinase signaling by Bacillus anthracis lethal toxin causes destabilization of interleukin-8 mRNA. Cell Microbiol. 8:130-138.
4. Blaustein RO, Koehler TM, Collier RJ, Finkelstein A. 1989. Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers. Proc. Natl. Acad. Sci. U. S. A. 86:2209 -2213.
5. Bourgogne A, Drysdale M, Hilsenbeck SG, Peterson SN, Koehler TM. 2003. Global effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids. Infect. Immun. 71:2736 -2743.
6. Brachman PS, et al. 1962. Field evaluation of a human anthrax vaccine. Am. J. Public Health Nations Health 52:632- 645.
7. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. 2001. Identification of the cellular receptor for anthrax toxin. Nature 414:225-229.
8. Chand HS, et al. 2009. Discriminating virulence mechanisms among Bacillus anthracis strains by using a murine subcutaneous infection model. Infect. Immun. 77:429-435.
9. Chen Z, et al. Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule. Proc. Natl. Acad. Sci. U. S. A. 108:739 -744.
10. Chopra AP, Boone SA, Liang X, Duesbery NS. 2003. Anthrax lethal factor proteolysis and inactivation of MAPK kinase. J. Biol. Chem. 278: 9402-9406.
11. Crawford MA, Aylott CV, Bourdeau RW, Bokoch GM. 2006. Bacillus anthracis toxins inhibit human neutrophil NADPH oxidase activity. J. Immunol. 176:7557-7565.
12. Drysdale M, et al. 2005. Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax. EMBO J. 24:221-227.
13. Duesbery NS, et al. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734 -737.
14. Erwin JL, et al. 2001. Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin. Infect. Immun. 69:1175-1177.
15. Escuyer V, Collier RJ. 1991. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells. Infect. Immun. 59:3381-3386.
16. Ezzell JW, et al. 2009. Association of Bacillus anthracis capsule with lethal toxin during experimental infection. Infect. Immun. 77:749 -755.
17. Fellows PF, et al. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247.
18. Firoved AM, et al. 2005. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am. J. Pathol. 167:1309 -1320.
19. Frevert CW, et al. 2002. Tissue-specific mechanisms control the retention of IL-8 in lungs and skin. J. Immunol. 168:3550 -3556.
20. Fritz DL, et al. 1995. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab. Invest. 73:691-702.
21. Green BD, Battisti L, Koehler TM, Thorne CB, Ivins BE. 1985. Demonstration of a capsule plasmid in Bacillus anthracis. Infect. Immun. 49: 291-297.
22. Guarner J, et al. 2003. Pathology and pathogenesis of bioterrorismrelated inhalational anthrax. Am. J. Pathol. 163:701-709.
23. Hahn AC, Lyons CR, Lipscomb MF. 2008. Effect of Bacillus anthracis virulence factors on human dendritic cell activation. Hum. Immunol. 69:552-561.
24. Heninger S, et al. 2006. Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax. Infect. Immun. 74:6067-6074.
25. Hepler RW, et al. 2006. A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection. Vaccine 24:1501-1514.
26. Hermanson G, et al. 2004. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl. Acad. Sci. U. S. A. 101:13601-13606.
27. Inglesby TV, et al. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236 -2252.
28. Ivins BE, et al. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16:1141-1148.
29. Reference deleted
30. Joyce J, et al. 2006. Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J. Biol. Chem. 281:4831- 4843.
31. Kirby JE. 2004. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect. Immun. 72:430-439.
32. Kobiler D, et al. 2006. Protective antigen as a correlative marker for anthrax in animal models. Infect. Immun. 74:5871-5876.
33. Kozel TR, et al. 2004. MAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc. Natl. Acad. Sci. U. S. A. 101:5042-5047.
34. Leppla SH. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. U. S. A. 79:3162-3166.
35. Li Q, et al. 2009. Anthrax LFn-PA hybrid antigens: biochemistry, immunogenicity, and protection against lethal Ames spore challenge in rabbits. Open Vaccine J. 2:92-99.
36. Lisanby MW, et al. 2008. Cathelicidin administration protects mice from Bacillus anthracis spore challenge. J. Immunol. 181:4989 -5000.
37. Loving CL, Kennett M, Lee GM, Grippe VK, Merkel TJ. 2007. Murine aerosol challenge model of anthrax. Infect. Immun. 75:2689 -2698.
38. Loving CL, et al. 2009. Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model. Infect. Immun. 77:255-265.
39. Lyons CR, et al. 2004. Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect. Immun. 72:4801- 4809.
40. Makino S, Uchida I, Terakado N, Sasakawa C, Yoshikawa M. 1989. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J. Bacteriol. 171:722-730.
41. Mayer-Scholl A, et al. 2005. Human neutrophils kill Bacillus anthracis. PLoS Pathog. 1:e23. c17 doi:10.1371/journal.ppat.0010023.
42. Mikesell P, Ivins BE, Ristroph JD, Dreier TM. 1983. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect. Immun. 39:371-376.
43. Mikszta JA, et al. 2006. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect. Immun. 74:6806-6810.
44. Mikszta JA, et al. 2005. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis. 191:278 -288.
45. Milne JC, Collier RJ. 1993. pH-dependent permeabilization of the plasma membrane of mammalian cells by anthrax protective antigen. Mol. Microbiol. 10:647- 653.
46. Milne JC, Furlong D, Hanna PC, Wall JS, Collier RJ. 1994. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 269:20607-20612.
47. Moayeri M, Haines D, Young HA, Leppla SH. 2003. Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J. Clin. Invest. 112:670-682.
48. Moayeri M, Leppla SH. 2009. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol. Aspects Med. 30:439-455.
49. Mogridge J, Cunningham K, Collier RJ. 2002. Stoichiometry of anthrax toxin complexes. Biochemistry 41:1079 -1082.
50. Mogridge J, Cunningham K, Lacy DB, Mourez M, Collier RJ. 2002. The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc. Natl. Acad. Sci. U. S. A. 99:7045-7048.
51. Mohamed N, et al. 2005. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect. Immun. 73:795- 802.
52. Molin FD, et al. 2008. Ratio of lethal and edema factors in rabbit systemic anthrax. Toxicon 52:824-828.
53. Muehlbauer SM, et al. 2007. Anthrax lethal toxin kills macrophages in a strain-specific manner by apoptosis or caspase-1-mediated necrosis. Cell Cycle 6:758 -766.
54. O'Brien J, Friedlander A, Dreier T, Ezzell J, Leppla S. 1985. Effects of anthrax toxin components on human neutrophils. Infect. Immun. 47:306-310.
55. Ostroff G, Axelrod DR, Bovarnick M. 1958. Antigenicity of polymers of glutamyl peptide on humans. Proc. Soc. Exp. Biol. Med. 99:345-347.
56. Pellizzari R, Guidi-Rontani C, Vitale G, Mock M, Montecucco C. 2000. Lethal factor of Bacillus anthracis cleaves the N terminus of MAPKKs: analysis of the intracellular consequences in macrophages. Int. J. Med. Microbiol. 290:421- 427.
57. Peterson JW, et al. 2007. Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect. Immun. 75:3414 -3424.
58. Pitt ML, et al. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19:4768-4773.
59. Popov SG, et al. 2002. Lethal toxin of Bacillus anthracis causes apoptosis of macrophages. Biochem. Biophys. Res. Commun. 293:349 -355.
60. Price BM, et al. 2001. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 69:4509-4515.
61. Rhie GE, et al. 2003. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc. Natl. Acad. Sci. U. S. A. 100: 10925-10930.
62. Ribot WJ, et al. 2006. Anthrax lethal toxin impairs innate immune functions of alveolar macrophages and facilitates Bacillus anthracis survival. Infect. Immun. 74:5029 -5034.
63. Rivera J, et al. Bacillus anthracis produces membrane-derived vesicles containing biologically active toxins. Proc. Natl. Acad. Sci. U. S. A. 107: 19002-19007.
64. Robertson DL, Tippetts MT, Leppla SH. 1988. Nucleotide sequence of the Bacillus anthracis edema factor gene (cya): a calmodulin-dependent adenylate cyclase. Gene 73:363-371.
65. Rosenshein MS, Price TH, Dale DC. 1979. Neutropenia, inflammation, and the kinetics of transfused neutrophils in rabbits. J. Clin. Invest. 64:580-585.
66. Schneerson R, et al. 2003. Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc. Natl. Acad. Sci. U. S. A. 100:8945- 8950.
67. Scobie HM, Rainey GJ, Bradley KA, Young JA. 2003. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. U. S. A. 100:5170 -5174.
68. Skoble J, et al. 2009. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax. Infect. Immun. 77:1649 -1663.
69. Spencer RC. 2003. Bacillus anthracis. J. Clin. Pathol. 56:182-187.
70. Taft SC, Weiss AA. 2008. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Clin. Vaccine Immunol. 15:71-75.
71. Tournier JN, et al. 2005. Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J. Immunol. 174:4934-4941.
72. Vasconcelos D, et al. 2003. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 83:1201-1209.
73. Vitale G, Bernardi L, Napolitani G, Mock M, Montecucco C. 2000. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 352 Pt. 3:739 -745.
74. Wang TT, Fellows PF, Leighton TJ, Lucas AH. 2004. Induction of opsonic antibodies to the gamma-D-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate. FEMS Immunol. Med. Microbiol. 40:231-237.
75. Wang TT, Lucas AH. 2004. The capsule of Bacillus anthracis behaves as a thymus-independent type 2 antigen. Infect. Immun. 72:5460 -5463.
76. Weiss S, et al. 2006. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect. Immun. 74:394 -398.
77. Welkos SL, Friedlander AM. 1988. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb. Pathog. 5:127-139.
78. Yee SB, Hatkin JM, Dyer DN, Orr SA, Pitt ML. 2010. Aerosolized Bacillus anthracis infection in New Zealand White rabbits: natural history and intravenous levofloxacin treatment. Comp. Med. 60:461-468.
79. Young JA, Collier RJ. 2007. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 76:243-265.
80. Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch. Pathol. Lab. Med. 122:982-992.
81. Zeng M, Xu Q, Pichichero ME. 2007. Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine. Vaccine 25:3588 -3594.